Data Science &
Statistical Modelling
Overview
Avalon’s core strengths are in leading edge data science, statistical analysis, modelling, and data-driven analytics. In our work in life sciences consulting, we have developed innovative approaches to the analysis of data on clinical processes, outcomes, and costs. In the development of economic models for life sciences, we have developed unique approaches beyond simple Markov models, making use of all the value attributes of a novel drug, device, or diagnostic. We bring these same advanced statistical tools into our work in law and economics and litigation.
Types Of Engagements
- Calculations of attributable costs using commercial claims data
- Estimating the usual, customary, and reasonable (UCR) amounts for pharmaceutical claims
- Statistical analysis to determine causative factors & liability
- Regression analysis to determine effects of an event
- Regression analysis to determine marginal effects of covariates
- Statistical models to predict expected versus actual utilization
- Novel analysis of real-world data (RWD)
- Systematic & comprehensive summaries of literature & evidence
Key Staff
- John Schneider, PhD
- Andrew Briggs, DPhil, MSc
- Anthony LoSasso, PhD
- Robert Ohsfeldt, PhD
- Cara Scheibling, MBA
- Jacie Cooper, MS
Related Markets & Industries
- Insurance & Third-Party Payers
- Attorneys & Law Firms
- Medical Services
- Hospitals & Health Systems
- Pharmaceuticals & Biotechnology
- Medical Devices & Diagnostics
- Private Equity & Venture Capital
- Consumer Products
- Public Health
- Government
Related Publications
- Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation. 2022
- Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. 2021
- Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. 2021
- An Attribution of Value Framework for Combination Therapies: Report by the Value Attribution Working Group. 2021
- A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. 2019
- Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study 2017
- Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. 2017
- Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks? 2015
- Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference ELicitation in TriAls (DELTA) Systematic Review. 2014
- Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. 2014
Related Issue Briefs
- Attributable Risk and Attributable Fraction: Litigation Applications (Issue Brief No. 57)
- Moving Beyond ‘Lives-Saved’ From COVID-19 (Issue Brief No. 50)
- Electronic Medical Records: Potential Issues in Litigation and Biomedical Research (Issue Brief No. 48)
- Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma (Issue Brief No. 47)
- Reference Pricing for in vivo and in vitro Diagnostic Tests (Issue Brief No. 32)
- Using Publicly Available Health Care Databases to Value & Price Medical Care Services (Issue Brief No. 1)